title: Alveolar targeting of aerosol pentamidine. Toward a rational delivery system.
abstract: Nebulizer systems that deposit a high proportion of aerosolized pentamidine on large airways are likely to be associated with marked adverse side effects, which may lead to premature cessation of treatment. We have measured alveolar deposition and large airway-related side effects (e.g., cough, breathlessness, and effect on pulmonary function) after aerosolization of 150 mg pentamidine isethionate labeled with 99mTc-Sn-colloid. Nine patients with AIDS were studied using three nebulizer systems producing different droplet size profiles: the Acorn System 22, Respirgard II, and Respirgard II with the inspiratory baffle removed. Alveolar deposition was greatest and side effects least with the nebulizer producing the smallest droplet size profile (Respirgard II), whereas large airway-related side effects were prominent and alveolar deposition lowest with the nebulizer producing the largest droplet size (Acorn System 22). Values for alveolar deposition and adverse airway effects were intermediate using the Respirgard with inspiratory baffle removed, thus indicating the importance of the baffle valve in determining droplet size. Addition of a similar baffle valve to the Acorn System 22 produced a marked improvement in droplet size profile. Selection of a nebulizer that produces an optimal droplet size range offers the advantage of enhancing alveolar targeting of aerosolized pentamidine while reducing large airway-related side effects.
authors.affiliation: Department of Thoracic Medicine, Royal Free Hospital, London, United Kingdom.
authors.forename: A K
authors.initials: AK
authors.lastname: Simonds
authors.forename: S P
authors.initials: SP
authors.lastname: Newman
authors.forename: M A
authors.initials: MA
authors.lastname: Johnson
authors.forename: N
authors.initials: N
authors.lastname: Talaee
authors.forename: C A
authors.initials: CA
authors.lastname: Lee
authors.forename: S W
authors.initials: SW
authors.lastname: Clarke
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000280:Administration, Inhalation; D000328:Adult; D000336:Aerosols; D003371:Cough / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D010419:Pentamidine / Q000008:administration & dosage* / Q000009:adverse effects; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D011650:Pulmonary Alveoli / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D016037:Single-Blind Method; D013667:Technetium; D017556:Technetium Compounds; D014001:Tin; D017971:Tin Compounds
chemical_list: D000336:Aerosols; D017556:Technetium Compounds; D017971:Tin Compounds; C033493:technetium Tc 99m tin colloid; D010419:Pentamidine; D013667:Technetium; D014001:Tin